Articles tagged with Multiple Sclerosis
A study published in Neurology found that people taking natalizumab for multiple sclerosis have a higher risk of developing JC virus-related infections, which can lead to fatal brain disease. Researchers monitored levels of anti-JC virus antibodies in patients treated with natalizumab and found a significant increase in risk.
Researchers identify microglia cells as primary cause of cognitive problems in MS patients, disrupting communication between nerve cells. The findings suggest that the disease's impact on cognition is more complex than previously thought, with potential new targets for treatment.
A study published in Nature Immunology identified Trabid, a protein regulator, as a key component in regulating interleukin genes and promoting autoimmune inflammation in multiple sclerosis patients. This finding suggests that Trabid may be a potential therapeutic target for treating inflammatory diseases such as MS.
A study found that taking high-dose vitamin D3 supplements can reduce the percentage of T cells related to MS activity, leading to a decrease in interleukin 17 levels. The results suggest that vitamin D may be an inexpensive, safe, and convenient treatment option for people with multiple sclerosis.
Researchers found that high doses of vitamin D3 supplements reduced inflammation and disease activity in people with relapsing-remitting MS. The study suggests vitamin D may be a potential treatment option for managing MS symptoms.
The study found that stromal cells, specialized fibers, and T helper 17 cells collaborate to form tertiary lymphoid tissues (TLTs) in the brain of MS patients. This discovery may lead to potential treatment options, such as targeted Th17 blockers, by understanding how TLTs are formed.
Multiple sclerosis may be triggered by the death of brain cells that make the insulation around nerve fibers. Nanoparticles have been shown to prevent progressive MS in an animal model, offering new hope for human treatments without side effects.
A new mouse model study suggests that the death of specific brain cells may trigger an autoimmune response against myelin, a characteristic of multiple sclerosis. Nanoparticle therapy has been shown to prevent this reaction, offering potential new treatments for humans.
Researchers identified a nuclear receptor protein called RXRgamma, which promotes OPC differentiation and remyelination. A vitamin D-activating drug may enhance remyelination in MS patients by controlling myelin sheath regeneration.
Researchers have found that Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus can infect and replicate in human neurons. This discovery suggests viral infection could underlie at least some symptoms of brain disorders such as Alzheimer's disease and multiple sclerosis.
Researchers at the University of Alberta have discovered a potential new pathway for treating multiple sclerosis by suppressing granzyme B, an enzyme that damages nerve cells. By inhibiting granzyme B with serpina3n, they found significant reduction in MS symptoms in human cells and pre-clinical models.
A Phase II randomized, placebo-controlled study found that taking estriol along with conventional medications helped RRMS patients avoid relapses. Estriol treatment improved cognition and prevented brain atrophy, potentially providing a one-two punch against the disease.
Researchers have developed a simple and rapid way to treat an immune-related disorder in mice, which could eventually help multiple sclerosis patients. The approach attaches disease-related protein fragments to spleen cells, preventing brain and spinal cord inflammation.
Researchers discovered that macrophages and monocytes actively participate in multiple sclerosis progression, exacerbating disease severity through stress signals. The study highlights the significance of the crosstalk between the peripheral immune system and brain, opening new avenues for potential therapies.
A study by University of Illinois researchers found participants with MS had significantly higher peak aerobic capacity and muscle strength when using computerized dynamometers and recumbent steppers. This challenges conventional methods that may underestimate participants' capabilities, highlighting the need for more effective exercis...
Scientists at the University of Adelaide have identified a key protein, CCR2, involved in a 'super-inflammatory' immune response driving multiple sclerosis (MS) and autoimmune diseases. Blocking this receptor may help control MS progression.
A recent study by McGill University researchers has made significant progress in understanding the mechanisms responsible for multiple sclerosis and identifying potential new treatments. By targeting a subset of B cells known as GM-CSF-producing B cells, the therapy shows promise in reducing disease activity.
Research found that long-chain fatty acids promote CNS reactive immune cells, while short-chain fatty acids regulate autoimmune responses. The study suggests a potential role for dietary interventions in managing multiple sclerosis.
A study published in Immunity suggests that dietary fat impacts the severity and duration of autoimmune flare-ups in mice. Short-chain fatty acids were found to alleviate symptoms by promoting regulatory T cells, while long-chain fatty acids exacerbated inflammation.
A study from the Gladstone Institutes reveals that a single drop of blood in the brain can trigger an autoimmune response akin to multiple sclerosis. Fibrinogen, a blood-clotting factor, activates microglia and recruits peripheral immune cells, causing myelin damage and inflammation.
A study of people with multiple sclerosis found that those who spent time in the sun every day during their teenage years developed the disease later than those who did not. The study also found that people who were overweight at age 20 developed the disease earlier than those who were average weight or underweight.
Researchers found that people with MS who experienced neuro-ophthalmic symptoms, such as blurred vision and nystagmus, performed poorly on visual neuropsychological tasks like the Symbol Digit Modalities Test (SDMT). This suggests that these individuals may have residual delays in visual processing speed.
Researchers at NYU Langone Health found that GANT61 increases myelin production by 50% and recruits neural stem cells to repair damaged areas of the brain. The treatment also improves symptoms in mice with multiple sclerosis, including paralysis and leg weakness.
Researchers found that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) can predict performance on daily living tasks. The study used Actual Reality technology to assess internet access and ordering tasks, showing poor BICAMS scores correlated with poor task performance.
Research reveals plummeting melatonin levels in spring and summer may trigger multiple sclerosis relapses. Melatonin treatment restored T cell balance and improved clinical symptoms in a mouse model of the disease.
A study published in Cell suggests that melatonin levels correlate with MS symptom severity, particularly during the fall and winter months. Researchers found that melatonin has a protective effect on immune cells, dampening the immune response and reducing disease progression.
A recent study published in JAMA Neurology found that continued smoking after an MS diagnosis is associated with accelerated disease progression. The study analyzed data from over 1,000 patients and found that those who continued to smoke converted to secondary progressive multiple sclerosis (SPMS) faster than those who quit.
Women with multiple sclerosis who breastfed exclusively for two months had a lower risk of relapse during the first six months after giving birth compared to those who did not breastfeed. Exclusive breastfeeding may reduce postpartum MS relapse risk but disease activity returns once regular feedings are introduced.
A new study published in Restorative Neurology and Neuroscience reports that mental visual imagery training can improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients, leading to better daily functioning and a greater sense of self-confidence.
A genetic study found an association between reduced vitamin D levels and increased risk of multiple sclerosis. The study, published in PLOS Medicine, used a Mendelian randomization approach to examine the link between genetically lowered vitamin D levels and susceptibility to multiple sclerosis.
Processing speed is a common variable limiting activity and participation in people with MS, according to Kessler Foundation researchers. This finding suggests that improving processing speed through targeted interventions may help individuals with MS maintain daily activities and stay employed.
A recent study published in Frontiers in Neurology found that poor sleep is a major factor in MS-related fatigue. The study, led by Dr. Lauren Strober, confirms that sleep disturbances account for up to 25% of the variance in fatigue among individuals with MS.
A new study suggests that regular exercise may help reduce disease activity in children with multiple sclerosis. Children who engaged in strenuous physical activity had lower overall volume of lesions in the brain and fewer relapses compared to those who did not.
New research suggests that high salt diets may exacerbate autoimmune neuroinflammation in individuals with specific genetic backgrounds, particularly females. The study found that mice fed a high salt diet exhibited worsened clinical signs of multiple sclerosis, while those with certain genetic variants showed no response to salt.
Researchers found that lack of confidence, physical and mental impairments, and environmental factors hinder people with MS from engaging in meaningful activities. Building confidence is crucial to overcome these barriers and promote healthy behaviors.
Researchers will examine how emotional processing deficits in MS are associated with social functioning across three levels. People with MS face difficulties recognizing universal emotions, leading to relationship issues and social isolation.
Researchers found that individuals with MS exhibit weaker connections between the dorsolateral prefrontal cortex and posterior brain regions, leading to slowed cognitive speed. The study suggests that therapies targeting white matter structures may help alleviate cognitive deficits.
A new study aims to understand MS pathology by activating metabolic stress in oligodendrocytes, a type of cell that produces myelin. The research seeks to determine if this nonimmune-mediated animal model can recapitulate MS pathology and find evidence for behavioral changes and cognitive decline.
A new nanobiosensor can detect biomarkers for multiple sclerosis and other nervous system diseases. By analyzing the interaction between a patient's cerebrospinal fluid and the device, doctors can rule out or confirm diagnoses with greater confidence.
A mechanism regulating plasma cell lifespan has been elucidated, identifying a promising new biomarker sBCMA for monitoring autoimmune diseases. The study shows that BCMA shedding is correlated with disease severity in multiple sclerosis and lupus patients.
The discovery of lymphatic vessels in the brain could have significant implications for understanding and treating neurological diseases such as autism, Alzheimer's, and multiple sclerosis. The findings, published in Nature, suggest that these vessels may play a major role in immune responses to neurodegenerative diseases.
Researchers found that innate lymphoid cells in males produce a protein that protects against the disease, while female mice remain inactive and do not produce this protein. This discovery opens up new avenues for investigation into sex-determined disease susceptibility.
Research suggests people with MS may have double the risk of dying early compared to those without the disease. Younger individuals with MS are particularly vulnerable, facing a three times higher risk of death.
A team at CHUM Research Centre and University of Montreal has identified a molecule called MCAM that could delay the onset of multiple sclerosis. Blocking this molecule may significantly slow disease progression.
Researchers have identified a faulty 'brake' within immune cells that drives excessive inflammation in multiple sclerosis. This discovery produces vital research tools and could lead to new therapies for the disease.
A study at Brigham and Women's Hospital discovered a genetic variant, SLC9A9, associated with patients' likelihood of responding to interferon-beta treatment. The variant may also play a role in regulating immune cells involved in inflammatory diseases like MS.
A study confirms that GM-CSF drives inflammation and neuronal damage in MS, explaining why INF-Beta is effective at reducing MS attacks. The cytokine is also identified as a potential target for new therapies.
Researchers at Gladstone Institutes discovered a way to prevent MS onset in mice by blocking SIRT1, suggesting its role in autoimmune disorders. The treatment also shows promise for other diseases like type I diabetes.
A new study reveals a sharp increase in MS drug costs over the past 20 years, with long-standing drugs like Betaseron and Copaxone seeing average annual price hikes of 21-36%. The study highlights the need for reform to address unsustainable pricing and ensure life-changing treatments remain accessible to patients.
A new study found that US multiple sclerosis drug prices have soared by 700% in two decades, with no drugs available for under $50,000 a year. The research highlights systemic problems in the pharmaceutical industry and a need for public awareness and involvement.
A Baltimore researcher has received a $260,000 award from the American Academy of Neurology to investigate the role of nitric oxide in multiple sclerosis. The goal is to examine the ability of selegiline and related drugs to alleviate disease symptoms in rodent models of MS.
Researchers at George Washington University and Case Western Reserve University have discovered two drugs that effectively treat multiple sclerosis by reversing the immune system's attack on nerve insulation, leading to increased remyelination. The study found that miconazole and clobetasol can promote myelination and enhance repair of...
Researchers discovered that netrin-1 regulates the blood-brain barrier by promoting tight junction proteins. Delivering netrin-1 to mice with MS improved symptoms, highlighting its potential therapeutic benefits.
A new study found that nearly 40% of multiple sclerosis patients who stopped taking their medication experienced some level of disease activity. Patients who stopped taking their medication were more likely to experience relapses and disability progression than those who continued treatment.
A study led by St. Jude Children's Research Hospital scientists identified a protein called NLRP12 that helps regulate inflammation in T cells. The findings suggest how mutations in the Nlrp12 gene cause disease, paving the way for developing targeted therapies to ease symptoms of autoinflammatory diseases like multiple sclerosis and c...
Researchers discovered two drugs, miconazole and clobetasol, that stimulate stem cells to repair white matter and reverse paralysis in multiple sclerosis. The study found that these compounds activate oligodendrocyte progenitor cells to increase myelination, potentially leading to new treatments for the disease.
A study of 1,964 patients found extending natalizumab dosing up to 8 weeks is well-tolerated and effective in treating MS disease activity. No cases of progressive multifocal leukoencephalopathy were reported in the extended dosing group.
Scientists at Case Western Reserve University found that two topical medicines can activate mouse and human brain stem cells, reversing paralysis and repairing damage caused by multiple sclerosis. The approach offers a potential new way to reverse disability in MS patients.
Researchers found that those taking phenytoin had 30% less damage to the nerve fiber layer and a 34% higher macula volume compared to placebo recipients. Vision recovery was successful, but long-term visual outcomes showed no significant differences between groups.
A Phase 2 study found that the experimental antibody anti-LINGO-1 significantly improved conduction in people with acute optic neuritis, a common precursor to multiple sclerosis. The treatment also led to improved recovery of myelin, a fatty substance surrounding nerves damaged in MS.